CAS 59831-65-1|halopemide
| Common Name | halopemide | ||
|---|---|---|---|
| CAS Number | 59831-65-1 | Molecular Weight | 416.876 |
| Density | 1.3±0.1 g/cm3 | Boiling Point | / |
| Molecular Formula | C21H22ClFN4O2 | Melting Point | / |
| MSDS | ChineseUSA | Flash Point | / |
| Symbol | GHS07 | Signal Word | Warning |
Names
| Name | N-[2-[4-(5-chloro-2-oxo-3H-benzimidazol-1-yl)piperidin-1-yl]ethyl]-4-fluorobenzamide |
|---|---|
| Synonym | More Synonyms |
halopemide BiologicalActivity
| Description | Halopemide is a potent phospholipase D (PLD) inhibitor, with IC50s of 220 and 310 nM for human PLD1 and PLD2, respectively. Halopemid is a dopamine receptors antagonist, and acts a psychotropic agent[1][2]. |
|---|---|
| Related Catalog | Research Areas >>CancerSignaling Pathways >>Metabolic Enzyme/Protease >>PhospholipaseSignaling Pathways >>GPCR/G Protein >>Dopamine ReceptorSignaling Pathways >>Neuronal Signaling >>Dopamine ReceptorResearch Areas >>Neurological Disease |
| Target | PLD1:220 nM (IC50) PLD2:310 nM (IC50) dopamine receptors |
| In Vitro | Halopemide (1-2 μM; 21 day) affects calcification in transdifferentiated MOVAS cells[3]. |
| In Vivo | Halopemide (10 mg/kg; p.o.) induces dyskinesias in the majority of monkeys tested[2]. |
| References | [1]. Scott SA, et al. Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat Chem Biol. 2009 Feb;5(2):108-17. [2]. Neale R, et al. Acute dyskinesias in monkeys elicited by halopemide, mezilamine and the "antidyskinetic" drugs, oxiperomide and tiapride. Psychopharmacology (Berl). 1981;75(3):254-7. [3]. Skafi N, et al. Phospholipase D: A new mediator during high phosphate-induced vascular calcification associated with chronic kidney disease. J Cell Physiol. 2019 Apr;234(4):4825-4839. |
Chemical & Physical Properties
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Molecular Formula | C21H22ClFN4O2 |
| Molecular Weight | 416.876 |
| Exact Mass | 416.141541 |
| PSA | 70.13000 |
| LogP | 4.47 |
| Index of Refraction | 1.612 |
| InChIKey | NBHPRWLFLUBAIE-UHFFFAOYSA-N |
| SMILES | O=C(NCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1)c1ccc(F)cc1 |
| Storage condition | 2-8°C |
Safety Information
| Symbol | GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H302 |
| Hazard Codes | Xn |
| RIDADR | NONH for all modes of transport |
Articles12
More Articles| CAY10593 inhibits the human P2X7 receptor independently of phospholipase D1 stimulation. Purinergic Signal. 9(4) , 609-19, (2013) The P2X7 receptor is a trimeric ATP-gated cation channel important in health and disease. We have observed that the specific phospholipase D (PLD)1 antagonist, CAY10593 impairs P2X7-induced shedding o... | |
| Halopemide, a new psychotropic agent. Cerebral distribution and receptor interactions. Pharm. Weekbl. Sci. 7(1) , 1-9, (1985) Halopemide is a new psychotropic agent, a structural analogue of the neuroleptics of the butyrophenone type but with different pharmacological and clinical properties. Preliminary clinical findings in... | |
| Dynamic cation-exchange systems for the separation of drugs derived from butyrophenone and diphenylpiperidine by high-performance liquid chromatography and applied in the determination of halopemide in plasma. J. Chromatogr. A. 164(2) , 177-85, (1979) Dynamic (solvent generated) cation-exchange systems for the separation of drugs and main metabolites derived from butyrophenone and diphenylpiperidine (haloperidol, pimozide, halopemide) were investig... |
Synonyms
| halopemide ( N-<2-<4-(5-chloro-2-oxo-1-benzimidazolinyl)piperidino>ethyl>-p-fluorobenzamide ) |
| Halopemidum |
| Halopemida |
| N-{2-[4-(5-Chloro-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl}-4-fluorobenzamide |
| N-(2-(4-(5-Chloro-2-oxo-1-benzimidazolinyl)piperidino)ethyl)-p-fluorobenzamide |
| 5-chloro-1-{1-[2-(4-fluoro-benzoylamino)-ethyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one |
| N-2-[4-(5-chloro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl-4-fluoro benzamide |
| N-{2-[4-(5-Chloro-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl]ethyl}-4-fluorobenzamide |
| R 34,301 |
| Benzamide, N-[2-[4-(5-chloro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]-4-fluoro- |
| halopemide |
| Halopemide (USAN/INN) |
| N-[2-[4-(5-Chloro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]-4-fluorobenzamide |
